THE PERITONEAL CANCER INDEX(PCI): SELTED REGIONS - AND NOT THE TOTAL PCI - ARE PREDICTIVE OF SURVIVAL IN ADVANCED OVARIAN CANCER

2017 ◽  
Author(s):  
Mikkel Rosendahl
Keyword(s):  
Ovarian Cancer ◽  
Peritoneal Cancer Index ◽  
Advanced Ovarian Cancer ◽  
Peritoneal Cancer

Prognostic value of peritoneal cancer index in primary advanced ovarian cancer

2018 ◽  
Vol 44 (1) ◽  
pp. 163-169 ◽  
Author(s):  
Antoni Llueca ◽  
Javier Escrig ◽  
A. Serra-Rubert ◽  
L. Gomez-Quiles ◽  
I. Rivadulla ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Prognostic Value ◽  
Peritoneal Cancer Index ◽  
Advanced Ovarian Cancer ◽  
Peritoneal Cancer

Accuracy and Reproducibility of the Peritoneal Cancer Index in Advanced Ovarian Cancer During Laparoscopy and Laparotomy

2013 ◽  
Vol 23 (9) ◽  
pp. 1699-1703 ◽  
Author(s):  
Sébastien Gouy ◽  
Jérémie Belghiti ◽  
Catherine Uzan ◽  
Geoffroy Canlorbe ◽  
Tristan Gauthier ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Confidence Interval ◽  
Cytoreductive Surgery ◽  
Peritoneal Cancer Index ◽  
Intraclass Correlation ◽  
Advanced Ovarian Cancer ◽  
Correlation Coefficients ◽  
Peritoneal Cancer ◽  
Senior Surgeon ◽  
The Mean

BackgroundThe aim of this prospective study was to evaluate the accuracy of the peritoneal cancer index (PCI) between laparoscopy and laparotomy and to evaluate the reproducibility of this index between 2 surgeons (junior vs senior) in advanced-stage ovarian cancer (ASOC). In ASOC, the quality of cytoreductive surgery, which is the main prognostic factor, is correlated with the extent of the disease and thus with the PCI. The reliability of this scoring index between different surgeons during laparoscopy and laparotomy has not been investigated in this disease.MethodsBetween April 2010 and October 2011, for each of the 29 patients undergoing complete cytoreductive surgery, 1 senior surgeon and 1 junior surgeon quantified the PCI score at 3 time points on the same day: during laparoscopy and during laparotomy, at the beginning and at the end. A concordance analysis was conducted with Bland and Altman’s method and estimated by intraclass correlation coefficients.ResultsThere was high concordance of the PCI score between the junior and senior surgeons during the laparoscopic and laparotomic procedures: the mean differences were not significantly different from 0 (P< 0.05) and 95% limits of agreement were ±3.5 and ±3.0, respectively. Laparoscopy underestimated the PCI score by approximately 2 points compared to the beginning of the laparotomy: the mean biases were −2.0 (95% confidence interval, −2.8 to −1.2) for the senior surgeon and −2.2 (95% confidence interval, −3.1 to 1.3) for the junior surgeon.ConclusionsThe PCI is reproducible and reliable for evaluating peritoneal spread in ASOC.

Peritoneal cancer index: a prognostic indicator of survival in advanced ovarian cancer

2003 ◽  
Vol 29 (1) ◽  
pp. 69-73 ◽  
Author(s):  
A.-A.K Tentes ◽  
G Tripsiannis ◽  
S.K Markakidis ◽  
C.N Karanikiotis ◽  
G Tzegas ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Peritoneal Cancer Index ◽  
Advanced Ovarian Cancer ◽  
Prognostic Indicator ◽  
Peritoneal Cancer

scholarly journals Central radiology assessment of the randomized phase III open-label OVHIPEC-1 trial in ovarian cancer

2020 ◽  
Vol 30 (12) ◽  
pp. 1928-1934
Author(s):  
Simone N Koole ◽  
Leigh Bruijs ◽  
Cristina Fabris ◽  
Karolina Sikorska ◽  
Maurits Engbersen ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Peritoneal Cancer Index ◽  
Disease Recurrence ◽  
Phase Iii ◽  
Ct Scans ◽  
Recurrence Free Survival ◽  
Open Label ◽  
Free Survival ◽  
Peritoneal Cancer

IntroductionHyperthermic intraperitoneal chemotherapy (HIPEC) improved investigator-assessed recurrence-free survival and overall survival in patients with stage III ovarian cancer in the phase III OVHIPEC-1 trial. We analyzed whether an open-label design affected the results of the trial by central blinded assessment of recurrence-free survival, and tested whether HIPEC specifically targets the peritoneal surface by analyzing the site of disease recurrence.MethodsOVHIPEC-1 was an open-label, multicenter, phase III trial that randomized 245 patients after three cycles of neoadjuvant chemotherapy to interval cytoreduction with or without HIPEC using cisplatin (100 mg/m2). Patients received three additional cycles of chemotherapy after surgery. Computed tomography (CT) scans and serum cancer antigen 125 (CA125) measurements were performed during chemotherapy, and during follow-up. Two expert radiologists reviewed all available CT scans. They were blinded for treatment allocation and clinical outcome. Central revision included Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 measurements and peritoneal cancer index scorings at baseline, during treatment, and during follow-up. Time to centrally-revised recurrence was compared between study arms using Cox proportional hazard models. Subdistribution models compared time to peritoneal recurrence between arms, accounting for competing risks.ResultsCT scans for central revision were available for 231 patients (94%) during neoadjuvant treatment and 212 patients (87%) during follow-up. Centrally-assessed median recurrence-free survival was 9.9 months in the surgery group and 13.2 months in the surgery+HIPEC group (HR for disease recurrence or death 0.72, 95% CI 0.55 to 0.94; p=0.015). The improved recurrence-free survival and overall survival associated with HIPEC were irrespective of response to neoadjuvant chemotherapy and baseline peritoneal cancer index. Cumulative incidence of peritoneal recurrence was lower after surgery+HIPEC, but there was no difference in extraperitoneal recurrences.ConclusionCentrally-assessed recurrence-free survival analysis confirms the benefit of adding HIPEC to interval cytoreductive surgery in patients with stage III ovarian cancer, with fewer peritoneal recurrences. These results rule out radiological bias caused by the open-label nature of the study.

Sign in / Sign up

Export Citation Format

Share Document